Ananda Developments PLC (AQSE:ANA) recently hired a contract research specialist in Australia to glean key insights on potential chronic pain treatment, MRX1. This evaluation, known as a pharmacokinetic (PK) study, aims to understand how MRX1 moves through the body—how it's absorbed, distributed, metabolised, and eventually excreted. The results will help researchers determine the safest and most effective dose for patients. PK studies are crucial in developing new medicines as they guide dosing decisions and ensure safety. To learn more, check out our detailed explainer [here].
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com